

GLAXOSMITHKLINE PLC  
Form 6-K  
July 19, 2016

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending 19 July 2016

GlaxoSmithKline plc  
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F  Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No

--

GlaxoSmithKline plc (the 'Company')

Transaction notification

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Sir Andrew Witty

b) Position/status CEO

c) Initial notification/ amendment Initial notification

Details of the issuer, emission allowance market

2. participant, auction platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc

b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Ordinary shares of 25 pence

Description of each ('Ordinary Shares')

a) The financial instrument ISIN: GB0009252882

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 14 July 2016 on Ordinary Shares held in the Company's 2009 Performance Share Plan.

b) Nature of The transaction

	Price(s)	Volume(s)
	£16.285	3.975
	£16.285	217.131
c) Price(s)	£16.285	580.125
and volume(s)	£16.285	1,329.326
	£16.285	3,988.006
	£16.285	5,452.053
	£16.285	5,905.210

Aggregated information

d) Aggregated volume 17,475.826  
Price £16.285

e) Date of the transaction 2016-07-14

Place of

f) the transaction n/a

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)  
Date: July 19, 2016

By: VICTORIA WHYTE

-----

Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc